AI Article Synopsis

  • Proton pump inhibitors (PPIs) like omeprazole have limited effectiveness in treating non-erosive reflux disease (NERD), prompting a study to evaluate the alternative treatment AlbisD, which contains ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate.
  • The study involved 126 patients and was designed to compare the efficacy and safety of AlbisD with omeprazole over 4 weeks, focusing on the percentage of patients experiencing complete heartburn cure at the end of the study.
  • Results show that AlbisD's effectiveness is comparable to omeprazole, with neither treatment showing significant differences in heartburn relief or safety, suggesting AlbisD could be

Article Abstract

Background/aims: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effective and safe in treating NERD. The aim of the study is to evaluate the efficacy and safety of AlbisD compared with omperazole in patients with NERD.

Methods: This was a multicenter, randomized, open-label, parallel-group, non-inferiority comparative study. A total of 126 patients with NERD were randomly allocated to either AlbisD twice daily or omeprazole 20 mg once daily for 4 weeks from February 2016 to August 2016. The study patients had histories of heartburn or regurgitation of moderate severity (> score 2) and a frequency of at least 2 episodes per week, and had no mucosal breaks of the esophagus on endoscopy. The primary efficacy variable was complete cure of heartburn at week 4. Secondary efficacy variables evaluating symptoms of heartburn and acid reflux as well as safety profiles were compared in the 2 groups at week 2 and 4 after treatment.

Results: A total of 113 patients completed the study (57 and 56 in AlbisD and omeprazole groups, respectively). The proportion of patients with complete cure of heartburn at week 4 was not significantly different between the AlbisD and omeprazole groups (35.1% vs 32.1% respectively, = 0.740). There were no significant differences between the 2 groups in the any secondary variables including proportions of days without heartburn or acid reflux over 4 weeks (including daytime and nighttime). Adverse events were similarly reported in the 2 groups (7 [12.3%] vs 6 [10.7%]), and there were no serious adverse events.

Conclusions: The efficacy and safety of AlibsD in treating NERD patients are not inferior to those of omeprazole. Therefore, AlbisD can be an alternative to PPIs for NERD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657924PMC
http://dx.doi.org/10.5056/jnm18185DOI Listing

Publication Analysis

Top Keywords

efficacy safety
12
safety albisd
8
albisd compared
8
non-erosive reflux
8
reflux disease
8
randomized open-label
8
treating nerd
8
complete cure
8
cure heartburn
8
heartburn week
8

Similar Publications

In the EU, conditional marketing authorization is a pragmatic tool for early approval of a medicine that fulfills an unmet medical need. In the pharmaceutical legislation, an unmet medical need means that a condition lacks a satisfactory method for diagnosis, prevention, or treatment. If such satisfactory methods exist, the new medicinal product must hold a major therapeutic advantage for those affected, meaning that it must demonstrate an improvement in efficacy or safety over existing methods or, in exceptional cases, a major improvement in patient care.

View Article and Find Full Text PDF

Typical Atrial Flutter: A Practical Review.

J Cardiovasc Electrophysiol

January 2025

Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.

Typical atrial flutter (AFL), defined as cavotricuspid isthmus (CTI)-dependent macro-re-entrant atrial tachycardia, often causes debilitating symptoms, and is associated with increased incidence of atrial fibrillation, stroke, heart failure, and death. Typical AFL occurs in patients with atrial remodeling and shares risk factors with atrial fibrillation. It is also common in patients with a history of prior heart surgery or catheter ablation.

View Article and Find Full Text PDF

Exploration of the feasibility of clinical application of phage treatment for multidrug-resistant -induced pulmonary infection.

Emerg Microbes Infect

January 2025

Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518112, China.

() commonly induces refractory infection due to its multidrug-resistant nature. To date, there have been no reports on the application of phage treatment for infection. This study was conducted to explore the feasibility of phage application in treating refractory infection by collaborating with a 59-year-old male patient with a pulmonary infection of multidrug-resistant Our experiments included three domains: ) selection of the appropriate phage, ) verification of the efficacy and safety of the selected phage, ) confirmation of phage-bacteria interactions.

View Article and Find Full Text PDF

Enhanced safety and efficacy profile of CD40 antibody upon encapsulation in pHe-triggered membrane-adhesive nanoliposomes.

Nanomedicine (Lond)

January 2025

Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.

Aim: To develop pH (pHe)-triggered membrane adhesive nanoliposome (pHTANL) of CD40a to enhance anti-tumor activity in pancreatic cancer while reducing systemic toxicity.

Materials And Methods: A small library of nanoliposomes (NL) with various lipid compositions were synthesized to prepare pH (pHe)-triggered membrane adhesive nanoliposome (pHTANL). Physical and functional characterization of pHTANL-CD40a was performed via dynamic light scattering (DLS), Transmission Electron Microscopy (TEM), confocal microscopy, and flow cytometry.

View Article and Find Full Text PDF

Objective: To explore the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) combined with a PD-1 antibody in improving complete clinical response (cCR) and organ preservation in patients with ultra-low rectal cancer.

Methods: This was a prospective phase II, single-arm, open-label trial. Patients with confirmed pMMR status T1-3aN0-1M0 retcal adenocarcinoma were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!